<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The WASID trial showed no advantage of <z:chebi fb="8" ids="10033">warfarin</z:chebi> over aspirin for preventing the primary endpoint of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, brain <z:mp ids='MP_0001914'>hemorrhage</z:mp>, or vascular <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In analyses of selected subgroups, there was no definite benefit from <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> reduced the risk of the primary endpoint among patients with basilar <z:mp ids='MP_0006135'>artery stenosis</z:mp>, but there was no reduction in <z:hpo ids='HP_0001297'>stroke</z:hpo> in the basilar artery territory or benefit for vertebral <z:mp ids='MP_0006135'>artery stenosis</z:mp> or posterior circulation disease in general </plain></SENT>
</text></document>